Oxford Biodynamics is releasing its EpiSwitch Prostate Screening blood test in both the US and UK markets early, the company announced on 26 September.
Oxford Biodynamics Releases EpiSwitch Prostate Cancer Test Early
The UK-based company is hoping to quickly take market share with its blood-based diagnostic that uses epigenetic data to assist cancer diagnosis.
